Otsuka reported new long-term kidney data intended to support Voyxact’s path from accelerated approval to full approval. The company said the Phase 3 study met its readout goal by stabilizing kidney function in the kidney-disease program. The new dataset is positioned as the key evidence package needed for regulators to upgrade the product’s approval status. The update arrives after accelerated approval, a pathway often used when earlier data suggest benefit while longer-term outcomes are still being collected. For patients and prescribers, a move to full approval would mark a shift from provisional regulatory status to a more complete benefit-risk assessment for a kidney indication where durability is central.